Personalis Brings Resistance Mutation Tracking to NeXT Personal® MRD Test

Real-Time Variant Tracker™ supplemental results track resistance and therapeutically targetable variants as cancer biology evolves.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the commercial launch of optional Real-Time Variant Tracker supplemental results in the NeXT Personal molecular residual disease (MRD) test report. These results identify clinically relevant resistance and therapeutically targetable variants over time, during NeXT Personal testing. Real-Time Variant Tracker includes variants with established clinical significance, including associations with FDA-approved therapies and recommendations in National Comprehensive Cancer Network® (NCCN®) guidelines.

“At Personalis, we have continued to push the boundaries of what’s possible with MRD testing, beginning with ultrasensitive detection and now with variant tracking,” said Richard Chen, MD, President & Chief Medical Officer of Personalis. “Real-Time Variant Tracker was developed in recognition that clinically informative variants, including resistance mutations, can emerge during MRD monitoring.”

“The ultrasensitivity of NeXT Personal allows us to detect very low levels of ctDNA, which can be particularly important when we’re monitoring patients whose disease may be difficult to assess through conventional measures alone,” said Dr. Leo Shunyakov, M.D., medical oncologist and hematologist at Central Care Cancer Center. “I see opportunities for highly sensitive ctDNA testing in settings including historically challenging tumor types such as earlier-stage breast and lung cancers. And as we follow patients over time, we’re not only asking whether disease is present, but also how the biology of the cancer may be changing. Real-Time Variant Tracker follows those changes over the course of NeXT Personal testing.”

Personalis first introduced Real-Time Variant Tracker through an Early Access Program in January 2026, giving select clinical and academic users an opportunity to incorporate the supplemental results in real-world clinical practice.

Availability

With today’s launch, Real-Time Variant Tracker becomes commercially available as an optional supplemental result in the NeXT Personal test report beginning October 20, 2026.

About Personalis, Inc.

At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect MRD and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and X (Twitter).

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts, including statements relating to: the attributes, advantages, capabilities, sensitivity, availability and clinical relevance of Personalis’ assays and products including the NeXT Personal test and optional Real-Time Variant Tracker supplemental results, the ability for Real-Time Variant Tracker to identify clinically relevant resistance and therapeutically targetable variants and inform new opportunities to optimize patient management, adoption of Real-Time Variant Tracker by physicians and Personalis’ biopharma partners, and the success of Personalis’ continued innovation in the MRD space. Such forward-looking statements involve known and unknown risks and uncertainties and other factors that may cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements, including the risks, uncertainties and other factors that relate to Personalis’ ability to demonstrate attributes, advantages or clinical validity of the NeXT Personal test and Real-Time Variant Tracker supplemental results, the NeXT Personal MRD assay remaining unique in its ability to detect traces of cancer in the ultrasensitive range and its ability to monitor mutations; future clinical data differing from the clinical data previously presented or expected results; the rate of adoption and use of the NeXT Personal test and Real-Time Variant Tracker; changes in health care policy, which could increase Personalis’ costs, decrease Personalis’ revenue, and impact sales of and reimbursement for Personalis’ tests; the impact of competition and macroeconomic factors on Personalis’ business; the partnering and/or collaboration arrangements that Personalis has entered into or may enter into in the future may not be successful, or may terminate, which could adversely impact Personalis’ business or affect its ability to develop and commercialize its services and products; having a limited number of suppliers; and customer concentration. These and other potential risks and uncertainties that could cause actual results to differ materially from the results predicted in these forward-looking statements are described under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Personalis’ Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. All information provided in this release is as of the date of this press release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. Personalis undertakes no duty to update this information unless required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261020218501/en/